

Supplementary Table 4. Number of events and incidence data of patients receiving SGLT2is versus GLP1-RAs in the original cohort after IPTW

Outcomes	SGLT2i			GLP1-RA		
	Event rate (%)	Total PY ^a	ID (95% CI)	Event rate (%)	Total PY ^a	ID (95% CI)
DR outcomes						
Any DR	2.6	38,508.7	15.6 (14.3–16.8)	2.8	18,323.9	19.3 (17.3–21.3)
Non-proliferative DR	2.1	38,649.8	12.6 (11.5–13.7)	1.8	18,480.3	12.1 (10.5–13.7)
Proliferative DR	0.56	39,124.6	3.3 (2.8–3.9)	1.0	18,567.5	7.0 (5.8–8.2)
Vitreoretinal interventions						
Intravitreal injection	0.34	39,194.1	2.0 (1.6–2.5)	0.50	18,676.7	3.4 (2.5–4.2)
Laser therapy	0.66	39,096.1	3.9 (3.3–4.6)	1.1	18,601.9	7.4 (6.1–8.6)
Vitrectomy	0.22	39,206.5	1.3 (1.0–1.7)	0.33	18,681.3	2.2 (1.5–2.9)
Composite surgical outcome ^b	0.97	39,019.6	5.8 (5.0–6.6)	1.6	18,527.8	11.1 (9.6–12.7)
Microvascular complications						
Diabetic nephropathy	3.6	38,303.7	22.0 (20.5–23.4)	4.5	18,036.8	31.2 (28.6–33.7)
Diabetic neuropathy	1.2	38,973.7	7.27 (6.43–8.12)	1.9	18,415.8	12.8 (11.1–14.4)
Macrovascular complications						
Myocardial infarction	0.67	39,140.3	4.04 (3.41–4.67)	0.64	18,696.5	4.31 (3.37–5.25)
Ischemic stroke	1.0	38,996.0	6.27 (5.49–7.06)	0.41	18,692.0	2.80 (2.04–3.56)
Major adverse limb events ^c	1.1	38,937.2	6.76 (5.94–7.58)	0.61	18,627.1	4.12 (3.20–5.04)
Cardiovascular death	0.64	39,275.2	3.81 (3.20–4.42)	0.69	18,723.2	4.68 (3.70–5.66)

SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP1-RA, glucagon-like peptide-1 receptor agonist; IPTW, inverse probability of treatment weighting; PY, person-year; ID, incidence density; CI, confidence interval; DR, diabetic retinopathy.

^aThe number of events per 1,000 person-years, ^bIndicates any intravitreal injection, laser therapy, or vitrectomy, ^cIndicates any peripheral arterial disease, claudication, critical limb ischemia, endovascular therapy, peripheral bypass, or nontraumatic amputation.